Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
What factors do you consider when determining whether to perform a biopsy for the diagnosis of organizing pneumonia?
Related Questions
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
What is your approach to evaluation and management of GERD in a patient with IPF?
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
What is your approach to treatment in a patient with radiographic UIP but pathologic evidence of both fibrotic NSIP and UIP?
How do you approach pre-operative risk assessment and optimization in a patient with interstitial lung disease?
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
